Desmopressin (DDAVP) Clinical Dosing and Safety Guidelines

Nocturnal Enuresis in Children

Initiate oral desmopressin 0.2 mg at bedtime; increase to 0.4 mg if needed, administered at least 1 hour before sleep, with evening fluid intake limited to ≤200 mL to prevent water intoxication. 1
Intranasal desmopressin (10–40 µg nightly, 1–4 sprays) may be used only when oral formulations are unavailable; this route carries a higher risk of hyponatremia. 1
Oral melt formulation (120–240 µg) should be taken 30–60 minutes before bedtime. 3
Desmopressin dosing for enuresis is not weight‑ or age‑based. 2
The maximal renal concentrating effect occurs 1–2 hours after administration. 2

Mandatory fluid restriction to ≤200 mL (≈6 oz) from the evening dose until morning is required to avoid water intoxication. 2
Polydipsia (excessive fluid intake) is an absolute contraindication to desmopressin therapy. 2
Intranasal formulations should be avoided in enuresis because they increase the risk of hyponatremia and seizures. 2
Serum electrolytes must be monitored during intercurrent illness to detect emerging hyponatremia. 1
Desmopressin is contraindicated in severe renal impairment (creatinine clearance < 30 mL/min); close monitoring is required when renal function is reduced. 3
Use is not recommended for isolated liver disease unless end‑stage renal disease is also present. 3

Perform a baseline urine dipstick and a 2‑day frequency‑volume chart before initiating therapy. 2
Conduct regular short drug holidays to evaluate ongoing need for desmopressin. 2
Expected therapeutic response in children with enuresis: ~30 % achieve complete dryness, ~40 % attain partial improvement. 2

Administer desmopressin 0.3 µg/kg intravenously, diluted in 50 mL saline and infused over 30 minutes, as first‑line therapy for mild hemophilia A or von Willebrand disease. 5
Von Willebrand disease affects approximately 1 in 100 individuals; desmopressin is a primary treatment option. 5
Routine use of desmopressin in bleeding trauma patients without a specific indication is not recommended. 5
Meta‑analyses have not confirmed an increased risk of thromboembolic complications with desmopressin use. 5

Do not use intranasal desmopressin for nocturnal enuresis because of the heightened hyponatremia and seizure risk. 2
Do not omit counseling on fluid restriction; inadequate restriction is the leading cause of water intoxication. 2
Do not continue therapy indefinitely without periodic drug holidays, as this prevents assessment of continued necessity. 2
Do not prescribe desmopressin to patients with polydipsia, an absolute contraindication. 2